Biotech's 40% Bear Market is Over

NASDAQ:IBB   iShares Biotechnology ETF
There is one useful way to determine when a trend is over and that is using a 50% "speedline" of a move.

The decline from $400 in $IBB, the IShares Nasdaq Biotechnology Index Fund back in July 2015 and then tumbled 40% to $240 on February 9th, 2016 and later retested $240 on June 27, 2016.

The mid-point of that decline is $320 and a line drawn from the top at $400 down through the $320 level on June 27th gives you a line that is now down below $275 and that line has been violated to the upside, retested and is turning back up again and THIS TIME it is with President Trump pushing for faster "time to market" in exchange for lower drug prices. Will the deal go through and will it make a difference? Time will tell.

For now, the Yellen-Bubble-popping bear market has been dramatic since August 2015 as it tumbled a whopping 40%.

But there might be signs of life here in Biotech Bubble land, even with fears of price gouging still lingering over these stocks .

For now: Average in over the next 2-3 months and see if this story pans out.


12:31AM EST February 2, 2017 280.42 last $IBB. Other symbols for Biotech $FBT, $XBI, $BBH
Comment: The obvious upper trendline violated this week and there is a reaction to that level here today 2/8/2017 (Wednesday). The rally in this leg reached well above the "Highest Low Trendline" that I prefer to use that gives a stronger insight into whether a trend is in place or not.

I am constructive about $IBB here on today's 2 point pullback. Add to positions here and on new highs and on each "average range advance".
Comment: Still very constructive chart formation. I added again to my position when it was down over a point today. 2/24/2017
Comment: IBB fell all the way back to the "TRUMP KEY LEVEL" from his "I will help drug companies push drugs through the FDA faster...

Subscribe to my indicator package KEY HIDDEN LEVELS $10/mo or $100/year and join me in the trading room KEY HIDDEN LEVELS here at TradingView.com

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.